Active Filter(s):
Details:
Under the agreement, CSI Pharmacy will get access for limited distribution rights to BPL's immune globulin product Gammaplex® (human immunoglobulin). Immune globulin products contain human antibodies, derived primarily from donated human plasma.
Lead Product(s): Human Immunoglobulin
Therapeutic Area: Immunology Product Name: Gammaplex
Highest Development Status: Approved Product Type: Large molecule
Recipient: CSI Pharmacy
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Agreement March 30, 2023
Details:
Coagadex® is the first and only treatment specifically for Hereditary Factor X Deficiency, a very rare inherited clotting disorder that causes problems with blood clotting due to not having enough Factor X in the blood.
Lead Product(s): Coagulation Factor X (Human)
Therapeutic Area: Hematology Product Name: Coagadex
Highest Development Status: Approved Product Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable May 04, 2022